At the time of writing, Evoke Pharma Inc [EVOK] stock is trading at $6.99, up 162.78%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EVOK shares have gain 162.78% over the last week, with a monthly amount glided 136.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Evoke Pharma Inc [NASDAQ: EVOK] stock has seen the most recent analyst activity on June 22, 2020, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $10 for it. Previously, H.C. Wainwright downgraded its rating to Neutral on March 05, 2019. On March 08, 2018, B. Riley FBR Inc. reiterated its Buy rating and revised its price target to $5 on the stock. Rodman & Renshaw reiterated its recommendation of a Buy and raised its price target to $9 on March 16, 2017. Laidlaw upgraded its rating to Buy for this stock on January 30, 2017, but kept the price target unchanged to $8. In a note dated January 05, 2017, Rodman & Renshaw upgraded an Buy rating on this stock and boosted its target price from $2.50 to $6.
For the past year, the stock price of Evoke Pharma Inc fluctuated between $1.94 and $12.32. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Evoke Pharma Inc [NASDAQ: EVOK] shares were valued at $6.99 at the most recent close of the market. An investor can expect a potential return of 157.51% based on the average EVOK price forecast.
Analyzing the EVOK fundamentals
According to Evoke Pharma Inc [NASDAQ:EVOK], the company’s sales were 11.59M for trailing twelve months, which represents an 77.48% jump. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.43%, Pretax Profit Margin comes in at -0.44%, and Net Profit Margin reading is -0.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -1.02 and Total Capital is -0.84. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.45 points at the first support level, and at 3.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.21, and for the 2nd resistance point, it is at 11.42.
Ratios To Look Out For
It is important to note that Evoke Pharma Inc [NASDAQ:EVOK] has a current ratio of 1.55. As well, the Quick Ratio is 1.50, while the Cash Ratio is 1.21. Considering the valuation of this stock, the price to sales ratio is 0.90, the price to book ratio is 1.79.
Transactions by insiders
Recent insider trading involved Nantahala Capital Management,, 10% Owner, that happened on Jan 28 ’25 when 41.0 shares were sold.
